Why CAR-T Can Work at Low Doses: Scientists Identify a Hidden ‘Elite’ Cell Subtype

A study found that treatment outcomes depend not on the total dose of CAR-T cell therapy but on the absolute number of a cell subtype with specific functional properties.

According to BioOn on the 18th (local time), researchers from Heidelberg University and other institutions identified shared cellular characteristics in patients who responded to low-dose CAR-T therapy in a paper published in the international journal Nature Communications.

The researchers conducted high-resolution single-cell analyses of patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma who participated in the HD-CAR-1 clinical trial.

The results showed that treatment response depended not on the total number of CAR-T cells administered but on the absolute number of a cell subtype with both “effector function” and “effector memory-like properties.”

This cell subtype secreted effector molecules that immediately eliminated tumors while also retaining the sustained anticancer capacity of memory cells. When the number of these cells exceeded a certain threshold, patients achieved deep remission even with a low total dose.

Conversely, when these cells were scarce, increasing the dose did not make a treatment effect likely.

The researchers extended their analysis to the patient blood collection material used as the starting material for CAR-T manufacturing. The blood of patients who responded to low doses was rich in T-cell precursors and myeloid cell subtypes favorable to T-cell differentiation.

By contrast, blood collected from patients whose treatment failed contained many myeloid cells with immunosuppressive functions. The researchers said this cellular composition causes CAR-T cells to differentiate into a dysfunctional phenotype.

The researchers said that preassessing specific immune cell subtypes in blood collection material could predict whether patients would benefit from a standard or low dose. This could help avoid ineffective treatment and potential adverse effects, they said.

The researchers added that focusing on expanding highly active cell subtypes rather than increasing total cell numbers could lower manufacturing costs and benefit patients who had been unable to receive treatment because of insufficient cell production.